Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Condition: Resectable Hepatocellular Carcinoma With High Risk of Recurrence
NCT07239245
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: None
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.